Utama › Obesiti › Florida › Hialeah
Kajian klinikal Obesiti di Hialeah, FL
13 kajian untuk Obesiti sedang mencari peserta di lokasi dalam dan sekitar Hialeah (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Mengambil pesertaFasa 2
- AGA Clinical Trials, Hialeah
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
Mengambil pesertaFasa 3
- Miguel Rebollar PA, Hialeah
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Mengambil pesertaFasa 3
- Elite Cardiac Research Center LLC, Hialeah
- Elite Clinical Research, Hialeah
- Panax Clinical Research, Miami Lakes · 4 mi jauh
- dan 2 lagi
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Mengambil pesertaFasa 2
- Indago Research & Health Center, Inc, Miami Lakes · 4 mi jauh
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Mengambil pesertaFasa 3
- Elite Cardiac Research Center LLC, Hialeah
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Mengambil pesertaFasa 2
- Indago Research & Health Center, Inc, Miami Lakes · 4 mi jauh
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Mengambil pesertaFasa 4
- NeoClinical Research, Hialeah
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Mengambil pesertaFasa 3
- Kailera Clinical Site, Miami Lakes · 4 mi jauh
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Mengambil pesertaFasa 3
- Indago Research and Health Center, Miami Lakes · 4 mi jauh
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Mengambil pesertaFasa 3
- San Marcus Research Clinic Inc, Miami Lakes · 4 mi jauh
- Indago Research and Health Center, Miami Lakes · 4 mi jauh
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Mengambil pesertaFasa 3
- Aga Clinical Trials, Hialeah
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Mengambil pesertaFasa 3
- Inpatient Research Clinic LLC, Miami Lakes · 4 mi jauh
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Mengambil pesertaFasa 3
- Angels Clinical Research Institute, Miami Lakes · 4 mi jauh
Kajian Obesiti di bandar lain
- Houston, TX43 kajian
- Chicago, IL41 kajian
- New York City, NY40 kajian
- San Antonio, TX40 kajian
- Washington, DC33 kajian
- Orlando, FL31 kajian
- Dallas, TX30 kajian
- Boston, MA28 kajian
- Las Vegas, NV27 kajian
- Miami, FL27 kajian
- Baltimore, MD25 kajian
- Jacksonville, FL25 kajian
Kajian lain di Hialeah
- Skizofrenia13 kajian
- Kegagalan Jantung12 kajian
- Diabetes Jenis 210 kajian
- Berat Badan Berlebihan10 kajian
- Penyakit Hati Steatotik9 kajian
- COPD8 kajian
- Gangguan Depresi Major8 kajian
- Aterosklerosis8 kajian
- Penyakit Alzheimer6 kajian
- Keadaan Pasca-COVID (Long COVID)6 kajian
- Kanser (semua jenis)6 kajian
- Penyakit Kardiovaskular6 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.